Clinical Trial Search

Primary: Phase 1: Maximum Tolerated Dose of Cabazitaxel — 30 mg/m^2

Primary: Dose-Escalation Phase: Number of Patients With Dose-Limiting Toxicities (DLTs) — 0; 1; 0; 1 Participants

Primary: Number of Participants With a Dose-limiting Toxicity (DLT) — 0; 2; 2; 1 Participants

Primary: To Establish the Safety and Tolerability of Single-agent AZD1775 in Patients With Refractory Solid Tumors — 6; 4; 6; 3 Participants

Primary: Number of Grade 3 or 4 Adverse Events, Highest Occurrence Per Participant — 1; 0; 0; 0 Adverse events

Primary: Parts 1, 2, 4, and 5: Number of Participants Who Experienced Dose-limiting Toxicities (DLTs) — 1; 1; 1; 2 Participants

Primary: Phase 2: Response Rate of This Combination in Participants With Colon Cancer, Non-small Cell Lung Cancer (NSCLC), and Granulosa Cell Ovarian Cancer — 0; 0; 0; 1…

Primary: Part 1: Percentage of Participants Who Experienced a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events, Version 4.0 (CTCAE 4.0) — 15.1…

Primary: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants

Primary: Maximum Tolerated Dose (MTD) — 180 Milligram (mg)

Primary: Maximum Tolerated Dose (MTD) of ISIS 183750 in Advanced Solid Tumors — 1000 mg

Primary: Percent of Participants Who Achieve a Sustained Progressive Disease (PD) Response, Defined to be at Least 4% Nuclear Area Positive (NAP) γH2AX at the Day 8 Biopsy — 44.4…

Primary: Pharmacokinetics (PK): Area Under the Concentration -Time Curve Over a Dosing Interval at Steady State (AUCt,ss) of Enzastaurin, It's Metabolites and Total Analytes in…

Primary: Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1 — 1; 2; 1; 1 Participants

Primary: Part 1A: Number of Participants Experiencing Dose Limiting Toxicity (DLT) — 0; 1; 0; 0 Participants